Novavax (NVAX) shares plummeted 5.07% in intraday trading on Friday, following reports that Trump health officials are planning to link coronavirus vaccines to the deaths of 25 children. This potential move, which could lead to restrictions on vaccine administration, has sent shockwaves through the pharmaceutical industry, particularly affecting vaccine manufacturers.

According to a Washington Post report, citing four anonymous sources familiar with the matter, the Trump administration is considering using data from the federal Vaccine Adverse Event Reporting System to establish this link. It's important to note that this system contains unverified reports of vaccine side effects and adverse experiences. The potential policy shift could significantly impact which Americans receive COVID-19 shots, raising concerns among vaccine producers and investors alike.

The news has had a broader impact on vaccine makers, with Moderna experiencing a more than 7% drop in share price. Pfizer, another major player in the COVID-19 vaccine market, also saw its stock slip by nearly 3%. This market reaction underscores the sensitivity of pharmaceutical stocks to regulatory news and public health policy shifts, especially in the context of the ongoing pandemic response.